

IN THE SPECIFICATION:

At page 2, please delete the paragraph beginning at line 12, and ending on line 21, and replace it with the following:

A 1

--It has surprisingly been found that the solid phase dispersion in accordance with this invention provides greatly reduced quinolone- or naphthyridonecarboxylic acid particle size. It has also been found that the dispersion provides acceptable solubility of the quinolone- or naphthyridonecarboxylic acid. It has also been found that the dispersion provides controlled release of the quinolone- or naphthyridonecarboxylic acid, which can be administered orally without any problems even to animals which will normally refuse formulations containing quinolone- or naphthyridone-carboxylic acid owing to their bitter taste. Unexpectedly, the solid phase dispersion has an outstanding acceptance when administered --

IN THE CLAIMS:

Please amend the claims as follows:

Sub
B1

A 2

1. (Amended). A solid phase dispersion comprising a quinolonecarboxylic acid- or naphthyridonecarboxylic acid in an insoluble matrix.
2. (Amended). The dispersion according to Claim 1, wherein the insoluble matrix is selected from the group consisting of shellac, high molecular weight polyethylene glycol, polyvinyl alcohol, poly(D.L.-lactic co glycolic and sugars.

A 3

4. (Amended). The dispersion of Claim 1, wherein quinolonecarboxylic acid- or naphthyridonecarboxylic acid and the insoluble matrix are in a ratio of 1:0.5 to 10.

5. (Amended). The dispersion of Claim 4, wherein quinolonecarboxylic acid- or naphthyridonecarboxylic acid and the insoluble matrix are in a ratio of 1:5.

6. (Amended). A method of preparing a solid dispersion of a quinolonecarboxylic acid- or naphthyridonecarboxylic acid, comprising forming a hydrate of the quinolonecarboxylic acid- or naphthyridonecarboxylic acid, mixing

Mo-6151